DXS International (STU:7EE) Other Financing: €0.05 Mil (TTM As of Apr. 2025)


STU:7EE DXS International PLC STU:7EE
39 GF Score
Price €0.01
GF Value €0.02
! 2 Warning Signs
View Full Analysis

What is DXS International Other Financing?

DXS International STU:7EE 39 Other Financing is €0.05 Mil as of Apr. 2025. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review.

DXS International's Other Financing for the six months ended in Apr. 2025 was €0.05 Mil.

DXS International's Other Financing for the trailing twelve months (TTM) ended in Apr. 2025 was €0.05 Mil.

DXS International Other Financing Historical Data

* Premium members only.

The historical data trend for DXS International's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Other Financing Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.04 0.05

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.04 0.05
STU:7EE
39GF Score
DXS International PLC STU:7EE
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DXS International Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Apr. 2025 was €0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.05 Mil mean?
DXS International (STU:7EE) has a Other Financing of €0.05 Mil as of Apr. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for DXS International and its competitors.
Is DXS International's Other Financing too high?
DXS International's current Other Financing is €0.05 Mil. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's Other Financing compare to VEEV and BTSG?
DXS International's Other Financing of €0.05 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for DXS International and its competitors. DXS International's current Other Financing is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current Other Financing of €0.05 Mil. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 45% below its estimated fair value. The current Other Financing is €0.05 Mil. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For DXS International (STU:7EE), the current Other Financing is €0.05 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DXS International (STU:7EE) Overvalued in 2026?

Based on GuruFocus' analysis, DXS International stock appears to be undervalued. The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.

Key valuation signals for STU:7EE:

  • Other Financing: €0.05 Mil
  • GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DXS International Business Description

Other Exchanges DXSP:UK
Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score

Get the complete analysis for STU:7EE

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price
€0.02
GF Value